Ruichu Technology

Ruichu Technology focuses exclusively on precision puncture surgical robots, developing CT-guided systems that integrate imaging technology with intelligent sensing capabilities for minimally invasive interventional procedures.

Company Overview

Founded in March 2019 in Shanghai, Ruichu Technology (上海睿触科技有限公司) was established by a team of professionals from the medical imaging and device engineering industries. The company’s founding philosophy centers on “知行合一、睿智触达” (Unity of Knowledge and Action, Intelligent Precision) — reflecting its commitment to translating advanced robotic technology into practical clinical solutions.

The founding team brings extensive experience from global medical device leaders. CEO Liu Jian holds a Ph.D. in Advanced Manufacturing from Shanghai Jiao Tong University and accumulated over 15 years of medical device R&D and management experience prior to founding Ruichu. His background includes positions at two of the GPS (GE, Philips, Siemens) medical imaging giants, as well as serving as R&D Director at a domestic medical imaging company.

Core Products

RC120 Puncture Surgical Navigation and Positioning System

The RC120 represents Ruichu Technology’s flagship product — a CT-guided lung puncture surgical robot that received NMPA Class III medical device registration in February 2024. The system incorporates what the company describes as a globally pioneering “CT imaging and intelligent sensing integrated technology.”

Key specifications:

• Positioning accuracy: Sub-millimeter mechanical precision
• Procedure time: 5-8 minutes (vs. ~30 minutes for conventional approaches)
• CT compatibility: Works with all CT systems of 16 slices or above
• CT scans required: Three standardized scans per procedure
• Space requirements: Integrates with CT scanning table without occupying floor space

The system enables percutaneous lung biopsy procedures with enhanced precision for targeting small nodules and complex anatomical locations. Clinical applications extend beyond diagnostic biopsy to include seed implantation, ablation therapy, targeted drug delivery, and preoperative localization of small lung nodules.

Technology & Innovation

Ruichu Technology’s core technical differentiator lies in its proprietary CT imaging and intelligent sensing integration platform. Unlike competing systems that rely on electromagnetic or optical tracking requiring markers and registration procedures, the RC120 eliminates these steps entirely, reducing cumulative positioning errors.

The technology addresses key challenges in lung puncture procedures:

• Respiratory motion compensation: Algorithms account for lung movement during breathing
• Complex anatomy navigation: Path planning through vessels and airways
• Radiation exposure reduction: Standardized three-scan protocol minimizes CT exposure for both patients and operators

The company has established intellectual property covering structural design, motion control, imaging algorithms, and artificial intelligence applications.

Development Pipeline

Beyond the RC120, Ruichu Technology is developing a platform-based surgical robot portfolio:

• Cardiovascular precision therapy robot: Currently in type testing and animal trial stages
• Laparoscopic surgical robot: In development phase

This pipeline strategy positions the company to expand from its puncture robot foundation into broader surgical robotics applications.

Market Presence

Ruichu Technology has established academic collaboration centers with hospitals across Shanghai, Anhui, Jiangsu, Guangdong, and Fujian provinces. These partnerships serve dual purposes: facilitating clinical adoption of the RC120 system while creating feedback channels for product refinement based on real-world surgical experience.

The company has also launched a remote “cloud operation” demonstration service, enabling physicians in different regions to experience the system through real-time high-definition video feeds from actual procedures.

Key Milestones

• 2019-03: Company founded in Shanghai
• 2024-02: RC120 Puncture Surgical Navigation and Positioning System receives NMPA Class III registration

Frequently Asked Questions

What products does Ruichu Technology offer?

Ruichu Technology’s primary product is the RC120 Puncture Surgical Navigation and Positioning System, a CT-guided robot for lung biopsy and interventional oncology procedures. The company is also developing cardiovascular therapy robots and laparoscopic surgical robots.

Is Ruichu Technology publicly traded?

No, Ruichu Technology is a privately held company. No stock code or public trading information is available.

What makes Ruichu Technology’s puncture robot different from competitors?

The RC120 uses proprietary CT imaging and intelligent sensing integration technology that eliminates the need for markers and registration procedures required by electromagnetic or optical tracking systems. This reduces procedural complexity and positioning errors while enabling sub-millimeter accuracy.